[go: up one dir, main page]

LT1966214T - Triazolopiridazinai kaip tirozino kinazės moduliatoriai - Google Patents

Triazolopiridazinai kaip tirozino kinazės moduliatoriai

Info

Publication number
LT1966214T
LT1966214T LTEP06847749.6T LT06847749T LT1966214T LT 1966214 T LT1966214 T LT 1966214T LT 06847749 T LT06847749 T LT 06847749T LT 1966214 T LT1966214 T LT 1966214T
Authority
LT
Lithuania
Prior art keywords
triazolopyridazines
tyrosine kinase
kinase modulators
modulators
tyrosine
Prior art date
Application number
LTEP06847749.6T
Other languages
English (en)
Inventor
Tianbao Lu
Richard Alexander
Richard W. Connors
Maxwell D. Cummings
Robert A. Galemmo
Heather Rae Hufnagel
Dana L. Johnson
Ehab Khalil
Kristi A. Leonard
Thomas P. Markotan
Anna C. Maroney
Jan L. Sechler
Jeremy M. Travins
Robert W. Tuman
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT1966214(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of LT1966214T publication Critical patent/LT1966214T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
LTEP06847749.6T 2005-12-21 2006-12-18 Triazolopiridazinai kaip tirozino kinazės moduliatoriai LT1966214T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75263405P 2005-12-21 2005-12-21
PCT/US2006/048241 WO2007075567A1 (en) 2005-12-21 2006-12-18 Triazolopyridazines as tyrosine kinase modulators

Publications (1)

Publication Number Publication Date
LT1966214T true LT1966214T (lt) 2017-02-10

Family

ID=37964498

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP06847749.6T LT1966214T (lt) 2005-12-21 2006-12-18 Triazolopiridazinai kaip tirozino kinazės moduliatoriai

Country Status (40)

Country Link
US (2) US8030305B2 (lt)
EP (1) EP1966214B9 (lt)
JP (1) JP5292102B2 (lt)
KR (1) KR101412675B1 (lt)
CN (1) CN101374843B (lt)
AP (1) AP3433A (lt)
AR (1) AR058703A1 (lt)
AU (1) AU2006331912B2 (lt)
BR (1) BRPI0620292B1 (lt)
CA (1) CA2634721C (lt)
CR (1) CR10170A (lt)
CY (1) CY1118846T1 (lt)
DK (1) DK1966214T3 (lt)
EA (1) EA015754B1 (lt)
EC (1) ECSP088573A (lt)
ES (1) ES2612377T3 (lt)
GT (1) GT200800105A (lt)
HN (1) HN2008000931A (lt)
HR (1) HRP20170103T1 (lt)
HU (1) HUE030390T2 (lt)
IL (1) IL192108A (lt)
LT (1) LT1966214T (lt)
MA (1) MA30084B1 (lt)
ME (1) ME02736B (lt)
MX (1) MX2008008277A (lt)
MY (1) MY159523A (lt)
NI (1) NI200800179A (lt)
NO (1) NO340958B1 (lt)
NZ (1) NZ568807A (lt)
PE (2) PE20110008A1 (lt)
PL (1) PL1966214T3 (lt)
PT (1) PT1966214T (lt)
RS (1) RS55630B1 (lt)
SV (1) SV2008002963A (lt)
TN (1) TNSN08278A1 (lt)
TW (1) TWI399378B (lt)
UA (1) UA98297C2 (lt)
UY (1) UY30041A1 (lt)
WO (1) WO2007075567A1 (lt)
ZA (1) ZA200806277B (lt)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1824340A4 (en) * 2004-12-17 2009-08-05 Bionovo Inc PROCESS FOR USING EXTRACTS OF SPECIES OF THE GENUS EPIMEDIUM
US7482029B2 (en) * 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
MX2008007049A (es) * 2005-11-30 2008-10-23 Vertex Pharma Inhibidores de c-met y usos de los mismos.
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PL2674428T3 (pl) 2006-04-07 2017-01-31 Vertex Pharmaceuticals Incorporated Modulatory transporterów z kasetą wiążącą ATP
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
PL2081937T3 (pl) * 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopirydazynowe modulatory kinaz białkowych
EP2407783A1 (en) 2006-10-27 2012-01-18 Janssen Pharmaceutica, N.V. A method for pharmacologically profiling compounds
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
MX2009005144A (es) 2006-11-22 2009-05-27 Incyte Corp Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa.
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
WO2008155378A1 (en) * 2007-06-21 2008-12-24 Janssen Pharmaceutica Nv Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
JP2010535815A (ja) * 2007-08-08 2010-11-25 バイオノボ・インコーポレーテッド モクセイ科トウネズミモチのエストロゲン性抽出物およびその使用
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2919870B1 (fr) * 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
FR2929613B1 (fr) * 2008-04-02 2010-12-31 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
AU2008296176A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family and uses thereof
AU2008296136A1 (en) * 2007-09-07 2009-03-12 Bionovo. Inc. Estrogenic extracts of Scuttelaria barbata D. Don of the Labiatae Family and uses thereof
JP2010539086A (ja) * 2007-09-07 2010-12-16 バイオノボ・インコーポレーテッド マメ科ファミリーのクズのエストロゲン性抽出物およびその使用
US20090068298A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. ESTROGENIC EXTRACTS OF Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family AND USES THEREOF
WO2009067555A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Scutellaria barbata extract and combinations for the treatment of cancer
CA2706313A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Methods of detecting and treatment of cancers using scuttelaria barbata extract
WO2009070478A2 (en) * 2007-11-19 2009-06-04 Bionovo, Inc. A process of making purified extract of scutellaria barbata d. don
EP2222321A4 (en) * 2007-11-19 2013-02-13 Bionovo Inc THERAPY AGAINST CANCER WITH AN EXTRACT OF SCUTELLARIA BARBATA
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
RU2499797C2 (ru) * 2008-02-05 2013-11-27 Санофи-Авентис Триазолопиридазины в качестве ингибиторов par1, их получение и применение в качестве лекарственных средств
CA2713554C (en) * 2008-02-05 2016-09-06 Sanofi-Aventis Imidazopyridazines as par1 inhibitors, production thereof, and use as medicaments
BRPI0907487A2 (pt) * 2008-02-05 2015-07-14 Sanofi Aventis Sais de triazólio como inibidores de par1, produção dos mesmos e uso como medicamentos
UY31676A1 (es) 2008-02-28 2009-09-30 "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
WO2009129260A2 (en) * 2008-04-14 2009-10-22 Bionovo, Inc. Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
AU2009244315A1 (en) * 2008-05-06 2009-11-12 Bionovo, Inc. Estrogenic extracts for use in treating vaginal and vulvar atrophy
NZ602791A (en) 2008-05-21 2014-04-30 Incyte Corp Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
CA2726982A1 (en) * 2008-06-05 2009-12-10 Bionovo, Inc. Method of quantification of multiple bioactives from botanical compositions
JP2011522822A (ja) * 2008-06-06 2011-08-04 バイオノボ・インコーポレーテッド エストロゲン受容体β媒介性病状の治療のためのダイオウ（Ｒｈｅｕｍｐａｌｍａｔｕｍ）由来のアントラキノンおよび類似体
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
FR2941229B1 (fr) * 2009-01-21 2012-11-30 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
AU2009272516A1 (en) * 2008-07-18 2010-01-21 Sanofi-Aventis Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as MET inhibitors
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
US20100069481A1 (en) * 2008-09-03 2010-03-18 Bionovo, Inc. Methods and compositions for the treatment of cancer
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
DK2361250T3 (da) 2008-12-22 2013-11-04 Merck Patent Gmbh Nye polymorfe former af 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-on-dihydrogenphosphat og fremgangsmåder til fremstilling deraf
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2010104843A2 (en) * 2009-03-09 2010-09-16 The Regents Of The University Of California Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
WO2010129343A2 (en) * 2009-04-28 2010-11-11 Bionovo, Inc. Method of reducing fat accumulation and inducing weight loss
US8389526B2 (en) * 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
CN102548995B (zh) * 2009-08-12 2015-01-28 诺华股份有限公司 杂环腙化合物以及它们治疗癌症和炎症的用途
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
ES2840454T3 (es) 2009-12-31 2021-07-06 Hutchison Medipharma Ltd Intermedio sintético útil en la preparación de inhibidores de c-Met triazolopiridínicos
AU2011269788B2 (en) 2010-02-03 2015-12-10 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA2797118C (en) * 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
ES2598530T3 (es) * 2010-07-14 2017-01-27 Betta Pharmaceuticals Co., Ltd. Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 有害生物防除剤としての新規複素環式化合物
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) * 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
KR20130091464A (ko) * 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
JP2015512447A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害薬の組合せおよびその使用
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
US9512119B2 (en) * 2012-07-27 2016-12-06 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound
CN103122000B (zh) 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CN104250257B (zh) * 2013-06-25 2017-06-16 上海翰森生物医药科技有限公司 3,4‑二氢‑1H‑苯并[c][1,2]噁硼酸类化合物或其可药用盐及其制备方法和用途
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
ES3014202T3 (en) * 2014-03-26 2025-04-21 Astex Therapeutics Ltd Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
RS62140B1 (sr) 2014-04-15 2021-08-31 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
TWI695837B (zh) * 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
AU2015360006B2 (en) * 2014-12-11 2020-07-16 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN106279176B (zh) * 2015-06-11 2020-09-08 中国科学院上海药物研究所 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用
TN2017000508A1 (en) 2015-06-26 2019-04-12 Takeda Pharmaceuticals Co 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
RU2747644C2 (ru) 2015-09-23 2021-05-11 Янссен Фармацевтика Нв Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака
HRP20201157T1 (hr) 2015-09-23 2020-11-13 Janssen Pharmaceutica N.V. Triciklički heterocikli za liječenje raka
CN105272995B (zh) * 2015-09-24 2017-10-27 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用
JP6787913B2 (ja) 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
CN106924260B (zh) * 2015-12-31 2018-05-25 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
JP7098600B2 (ja) * 2016-08-16 2022-07-11 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ３Ｈ－イミダゾール［４，５－ｃ］ピリジン誘導体を有機金属亜鉛－アミン塩基と反応させることによる２－（３，６－ジハロピリジン－２－イル）－３Ｈ－イミダゾール［４，５－ｃ］ピリジン誘導体及び関連化合物の製造方法
PL3548033T3 (pl) * 2016-11-28 2025-06-02 Praxis Precision Medicines, Inc. Związki i sposoby ich stosowania
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
TWI774755B (zh) * 2017-04-28 2022-08-21 日商佐藤製藥股份有限公司 二氟甲烯化合物之製造法
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2019201718A1 (en) * 2018-04-18 2019-10-24 Basf Se D-glucaro-6,3-lactone monoester and a process for the preparation thereof
CN112423760A (zh) 2018-05-30 2021-02-26 普拉克西斯精密药物股份有限公司 离子通道调节剂
CN109045036B (zh) * 2018-07-19 2020-10-02 中山大学 [1,2,4]三唑并[4,3-b]哒嗪衍生物在制备抗肿瘤药物中的应用
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
EP3893872B1 (en) 2018-12-14 2024-07-17 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN110156805B (zh) * 2019-05-22 2020-12-11 南京合巨药业有限公司 一种2, 3-二氢-1, 4-二氧代[2,3-b]吡啶-7-羧酸的制备方法
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
WO2021222045A1 (en) * 2020-04-26 2021-11-04 Apollomics Inc. Novel pharmaceutical formulation for c-met inhibitor
TWI728882B (zh) 2020-07-28 2021-05-21 祥昇機電工業有限公司 自吸式抽水機之釋氣機構
CN117412973A (zh) * 2021-05-31 2024-01-16 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
TWI872642B (zh) * 2022-08-09 2025-02-11 大陸商上海濟煜醫藥科技有限公司 含氮雜環化合物作為泛素-特異性蛋白酶１抑制劑的製備方法、應用及其用途
WO2025007275A1 (zh) * 2023-07-04 2025-01-09 北京浦润奥生物科技有限责任公司 [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171798A (en) * 1876-01-04 Improvement in spring attachments for cradles
US147568A (en) * 1874-02-17 Improvement in paper-folding attachments for printing-presses
US111495A (en) * 1871-01-31 Stinb
US96322A (en) * 1869-11-02 Improvement in combined cultivator and seed-planter
US181455A (en) * 1876-08-22 Improvement in brooms
US138264A (en) * 1873-04-29 Improvement in machines for cutting out planchets of sheet metal
US192696A (en) * 1877-07-03 Improvement in combined cut-off and filter
US16625A (en) * 1857-02-10 Arraitg-ement of springs for vehicles
US261297A (en) * 1882-07-18 Mortar for stamp-mills
US17309A (en) * 1857-05-12 Portable gas co
NL128591C (lt) 1965-07-02
US3506656A (en) * 1966-10-22 1970-04-14 Boehringer Mannheim Gmbh Triazolo-tetrazolo-pyridazine derivatives
NL130097C (lt) 1966-10-22
DE2222834A1 (de) 1972-05-10 1973-11-29 Boehringer Mannheim Gmbh Nitrofuryl-amidin-derivate und verfahren zur herstellung derselben
US3823137A (en) * 1970-06-20 1974-07-09 Boehringer Mannheim Gmbh Novel nitrofuran compounds and pharmaceutical compositions
DE2030581A1 (de) 1970-06-20 1971-12-30 Boehringer Mannheim GmbH, 6800 Mannheim-Waldhof Nitrofuryl-amidin-Derivate und Verfahren zur Herstellung derselben
DE2161587A1 (de) 1971-12-11 1973-06-14 Boehringer Mannheim Gmbh Nitrofuryl-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazinderivat
GB1324060A (en) 1971-03-19 1973-07-18 Boehringer Mannheim Gmbh Nitrofuryl-triazolo 4,3-b pyridazine derivatives
DE2113438A1 (de) 1971-03-19 1972-09-21 Boehringer Mannheim Gmbh Nitrofuryl-triazolo[4,3-b]pyridazinderivate
DE2147013A1 (de) * 1971-09-21 1973-03-29 Boehringer Mannheim Gmbh Antimikrobiell wirksame nitrofuranderivate und verfahren zur herstellung derselben
JPS5612390A (en) * 1979-07-10 1981-02-06 Yoshitomi Pharmaceut Ind Ltd Triazolopyridazine derivative
US4260755A (en) * 1979-10-31 1981-04-07 American Cyanamid Company Novel 6-phenyl and substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines
FR2562071B1 (fr) 1984-03-30 1986-12-19 Sanofi Sa Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
CA2044564A1 (en) 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
US5278161A (en) * 1990-06-28 1994-01-11 Hoffmann-La Roche Inc. Amino acid derivatives useful as renin inhibitors
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
JPH06331089A (ja) 1993-05-18 1994-11-29 Asahi Organic Chem Ind Co Ltd プラスチック管の電気溶着方法
TW304878B (lt) 1993-09-21 1997-05-11 Takeda Pharm Industry Co Ltd
DE69623455T2 (de) 1995-04-19 2003-01-16 Schneider (Usa) Inc., Plymouth Beschichteter dilatator zur abgabe eines arzneistoffs
US20020111495A1 (en) * 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
GB9718254D0 (en) * 1997-08-28 1997-11-05 Merck Sharp & Dohme Therapeutic agents
US6297235B1 (en) * 1997-08-28 2001-10-02 Merck Sharp & Dohme Ltd. Triazolopyridazine derivatives for treating anxiety and enhancing cognition
US6579875B1 (en) * 1998-01-21 2003-06-17 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for GABA receptors
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
CA2388593A1 (en) * 1999-11-12 2001-05-17 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
ATE293109T1 (de) 2001-01-31 2005-04-15 Pfizer Prod Inc Nikotinsäureamid-derivate und ihre mimetika als inhibitoren von pde4-isozyms
US7250518B2 (en) * 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
WO2002085888A1 (fr) 2001-04-20 2002-10-31 Sanofi-Synthelabo Tetrahydropyridyl-alkyl-heterocycles, procede pour leur preparation et compositions pharmaceutiques les contenants
EP1446110A2 (en) 2001-10-16 2004-08-18 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
CN1281606C (zh) * 2002-03-01 2006-10-25 安斯泰来制药有限公司 含氮杂环化合物
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6793457B2 (en) * 2002-11-15 2004-09-21 General Electric Company Fabricated repair of cast nozzle
RU2005122484A (ru) * 2002-12-18 2006-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, используемые в качестве ингибиторов протеинкиназ
US20060173009A1 (en) * 2003-01-07 2006-08-03 Hiroyuki Kanoh Agent inducing increase in bone mass
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
US7250417B2 (en) * 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
US7037909B2 (en) * 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
MX2008007049A (es) * 2005-11-30 2008-10-23 Vertex Pharma Inhibidores de c-met y usos de los mismos.
CA2651979A1 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met

Also Published As

Publication number Publication date
PE20110008A1 (es) 2011-01-31
RS55630B1 (sr) 2017-06-30
AR058703A1 (es) 2008-02-20
ZA200806277B (en) 2010-09-29
HRP20170103T1 (hr) 2017-03-24
AU2006331912B2 (en) 2012-08-30
MA30084B1 (fr) 2008-12-01
CR10170A (es) 2008-11-24
ECSP088573A (es) 2008-07-30
CN101374843B (zh) 2012-09-05
NI200800179A (es) 2016-01-06
US8173654B2 (en) 2012-05-08
CA2634721C (en) 2014-06-17
NO340958B1 (no) 2017-07-31
BRPI0620292B1 (pt) 2021-08-24
EA015754B1 (ru) 2011-12-30
JP2009525263A (ja) 2009-07-09
EP1966214B1 (en) 2016-11-02
US20070203136A1 (en) 2007-08-30
AP3433A (en) 2015-10-31
NO20083013L (no) 2008-09-19
CA2634721A1 (en) 2007-07-05
BRPI0620292A2 (pt) 2011-11-08
US20090098181A1 (en) 2009-04-16
UY30041A1 (es) 2007-05-31
TNSN08278A1 (en) 2009-10-30
CN101374843A (zh) 2009-02-25
KR101412675B1 (ko) 2014-07-03
US8030305B2 (en) 2011-10-04
IL192108A (en) 2014-02-27
WO2007075567A1 (en) 2007-07-05
TWI399378B (zh) 2013-06-21
IL192108A0 (en) 2008-12-29
DK1966214T3 (en) 2017-02-13
MX2008008277A (es) 2009-03-04
UA98297C2 (en) 2012-05-10
JP5292102B2 (ja) 2013-09-18
EP1966214B9 (en) 2017-09-13
EP1966214A1 (en) 2008-09-10
ES2612377T3 (es) 2017-05-16
AP2008004502A0 (en) 2008-06-30
KR20080085154A (ko) 2008-09-23
HUE030390T2 (en) 2017-05-29
ME02736B (me) 2017-10-20
AU2006331912A1 (en) 2007-07-05
SV2008002963A (es) 2010-01-18
PL1966214T3 (pl) 2017-04-28
PT1966214T (pt) 2017-02-03
PE20070752A1 (es) 2007-08-13
TW200801007A (en) 2008-01-01
MY159523A (en) 2017-01-13
CY1118846T1 (el) 2018-01-10
GT200800105A (es) 2008-10-10
EA200870085A1 (ru) 2008-12-30
HN2008000931A (es) 2013-10-22
NZ568807A (en) 2011-05-27

Similar Documents

Publication Publication Date Title
ZA200806277B (en) Triazolopyridazines as tyrosine kinase modulators
IL187693A0 (en) Aminopyrimidines as kinase modulators
IL187686A0 (en) Aminopyrimidines as kinase modulators
IL180790A0 (en) Pyrrolo-pyridine kinase modulators
GB2448245B (en) Optical authentication
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
IL184657A0 (en) Adam-9 modulators
IL197015A0 (en) Benzotriazole kinase modulators
IL191880A0 (en) Compounds having cytokine modulating properties
IL187692A0 (en) Alkylquinoline and alkylquinazoline kinase modulators
IL189846A0 (en) Theramutein modulators
IL187895A0 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
GB0600254D0 (en) Stereomicroscope
ZA200801986B (en) Standard
GB0526422D0 (en) Authentication
GB0405985D0 (en) Kinase
ZA200710136B (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ZA200800275B (en) Aminopyrimidines as kinase modulators
ZA200800274B (en) Aminopyrimidines as kinase modulators
ZA200800272B (en) Alkylquinoline and alkylquinazoline kinase modulators
GB0517246D0 (en) Prioritisation scheme
ZA200804747B (en) Compounds having cytokine modulating properties
GB0603829D0 (en) No knots
HK1116060A (en) Aminopyrimidines as kinase modulators